Cancer Cell Signaling Prgm

癌细胞信号(CCS)计划是一个新形成的计划，其结果是重组 以前的癌细胞生物学计划变成了两个更有凝聚力的计划[另一个是癌症分子 遗传学计划(CMG)]。CCS计划由来自6个国家的18名研究人员组成的多学科小组 医学院和人文学院的学术部门，他们分享 共同感兴趣的是阐明控制肿瘤细胞的细胞和分子信号事件 行为和生存。他们还分享了最重要的科学目标：1)研究生物活性的作用 脂质在肿瘤形成中的作用；2)识别癌细胞中受干扰的关键信号通路；3) 了解代谢物、炎症、生物能量学、基因和环境之间的相互作用 影响肿瘤发生的因素；以及4)根据 了解癌细胞的信号转导，并开发合理的基础来组合这些抑制剂。这个 CCS计划也有很强的临床前推动力，研究人员利用异种移植和转基因 寻求开发涉及通过调节各种信号转导起作用的制剂的治疗方法的模型 网络。CCS计划的资金基础约为每年680万美元的直接支持， 其中6.25美元来自NIH和其他同行审查的资金来源。基金基数包括9个基金 来自NCI的项目，每年的直接成本总计140万美元。CCS促进了Intra和 通过在整个计划中组织研讨会和定期会议，实现计划间的互动 成员资格，以及具有重叠研究兴趣的重点讨论小组，导致 许多联合出版物和新的合作赠款。这一广泛的、跨学科的成功 CCS项目研究人员260人的跟踪记录证明了癌症研究的方法 2008年以来的出版物，其中15%代表方案内合作，34%代表方案间合作 协作，以及5%的计划内和计划间协作，以及在开发 已从基础实验室研究进展到8个多机构临床I/II期试验的倡议 与弗吉尼亚联邦大学(VCU)梅西癌症中心(MCC)的其他项目合作。

The Cancer Cell Signaling (CCS) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two more cohesive programs [the other being the Cancer Molecular Genetics program (CMG)]. The CCS program consists of a multidisciplinary group of 18 investigators from 6 academic departments from the School of Medicine and the College of Humanities and Sciences, who share a common interest in elucidation of cellular and molecular signaling events governing neoplastic cell behavior and survival. They also share the overarching scientific goals of: 1) examining the role of bioactive lipids in tumor formation; 2) identifying key signaling pathways that are perturbed in cancer cells; 3) understanding the interactions among metabolites, inflammation, bioenergetics, genes, and the environment that affect tumorigenesis; and 4) identifying potential therapeutic targets and strategies based upon an understanding of cancer cell signaling and to develop a rational basis for combining inhibitors of these. The CCS program also has a strong pre-clinical thrust with investigators utilizing xenograft and transgenic models seeking to develop treatments involving agents that act by modulating various signal transduction networks. The CCS program has a funding base of roughly $6.8 million dollars in annual direct support, of which $6.25 is from NIH and other peer-reviewed funding sources. The funding base includes 9 funded projects from NCI with a total of $1.4 million in annual direct costs. CCS fosters the development of intra and inter-programmatic interactions by organizing seminars and regular meetings among the entire program membership, as well as focused discussion groups with overlapping research interests that have led to numerous co-publications and new collaborative grants. The success of this broad, interdisciplinary approach to cancer research is demonstrated by the track record of CCS program investigators with 260 publications since 2008 of which 15% represent intra-programmatic collaborations, 34% represent inter-programmatic collaborations, and 5% both intra and inter-programmatic collaborations, and in developing initiatives that have progressed from basic laboratory studies to 8 multi-institutional clinical Phase I/II trials with other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs.